Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
Clinical trial NCT03227029 · COMPLETED
Trial details
- NCT number
- NCT03227029
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-22
- Primary completion
- 2019-12-19
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.